The push to $80m was largely on them talking up the move to internal oncology they’ve now dropped & gone back to the ffp/eet delivery (which i always thought was their best avenue although not as lucrative). All 5 previous big pharma deals, Genentech still active have progressively increased in size each 10-20% larger thab the one before it (if you forget the potential expansions with janssen). The next deal whilst still being long awaited would really need to be 10-20% bigger than Genentech to really look like a change.
Ann: Appointment of Non-Executive Director and Appendix 3X, page-18
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.29 |
Change
0.045(3.63%) |
Mkt cap ! $749.4M | |||
| Open | High | Low | Value | Volume |
| $1.25 | $1.29 | $1.25 | $337.0K | 265.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $1.23 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.29 | 58344 | 1 |
View Market Depth
| Last trade - 16.10pm 25/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |